Source comparison
CJC-1295 No DAC & Ipamorelin Sleep: Comparison of Peptide Sleep Protocols
Before selecting a peptide stack for sleep enhancement, understanding how different protocols compare across mechanism, side effect profile, and sleep architecture impact is essential. CJC-1295 no DAC + Ipamorelin Dual GHRH + ghrelin receptor activation produc
This comparison does not assign a generated winner or score.
- Before selecting a peptide stack for sleep enhancement, understanding how different protocols compare across mechanism, side effect profile, and sleep architecture impact is essential.
- CJC-1295 no DAC + Ipamorelin
- Dual GHRH + ghrelin receptor activation producing pulsatile GH release
- 22–30% increase in slow-wave sleep duration (polysomnography-verified)
- Minimal. Transient water retention, rare lightheadedness during first week
- 5 days on / 2 days off; 4–6 week break after 12 weeks
- Gold standard for sleep architecture optimisation without DAC-related complications
- CJC-1295 with DAC + Ipamorelin
- Extended half-life GHRH analogue + ghrelin agonist creating sustained GH elevation
- 15–20% increase but with disrupted natural GH pulsatility
- Moderate. Joint pain, insulin resistance, blunted cortisol response reported in 25–40% of users
- Continuous use possible but not recommended beyond 16 weeks
- DAC modification extends half-life but compromises natural hormone rhythm. Not ideal for sleep-focused protocols
- GHRP-6 + CJC-1295 no DAC
- GHRH analogue + non-selective ghrelin agonist
- 18–25% increase but with elevated hunger signaling
- Moderate to high. Significant appetite increase, cortisol and prolactin elevation
- 5 days on / 2 days off; break after 10 weeks
- Effective for GH release but appetite stimulation and hormonal side effects limit sleep-specific application
- Ipamorelin monotherapy
- Selective ghrelin receptor agonist
- 10–15% increase (less pronounced without GHRH pathway synergy)
- Very low. Virtually no cortisol, prolactin, or appetite effects
- Minimal cycling required
- Safe and well-tolerated but lacks the synergistic amplification of combined protocols
- MK-677 (Ibutamoren) oral
- Oral ghrelin mimetic producing sustained GH and IGF-1 elevation
- 12–18% increase but with next-day grogginess reported in 30% of users
- Moderate. Appetite increase, insulin resistance with chronic use, water retention
- Continuous daily use up to 24 weeks
- Oral convenience but sustained GH elevation disrupts natural pulsatility. Injectable peptides offer superior sleep architecture outcomes
- The CJC-1295 no DAC and Ipamorelin combination remains the most research-supported protocol for sleep quality enhancement specifically because it preserves natural GH pulsatility while amplifying pulse magnitude. Alternatives either introduce unwanted side effects (GHRP-6, MK-677) or compromise natural hormone rhythms (CJC-1295 with DAC). For researchers prioritising measurable improvements in slow-wave sleep duration without systemic hormonal disruption, the no-DAC formulation paired with Ipamorelin represents the optimal balance of efficacy and safety.